Quickly supply alternative strategic theme areas vis-a-vis B2C mindshare. Objectively repurpose stand-alone synergy via user-centric architectures.

FOLLOW US ON:

Recent Posts

Get in touch!

Fusce varius, dolor tempor interdum tristiquei bibendum service life.

147/I, Green Road, Gulshan Avenue, Panthapath, Dhaka

Industry News

The Globe and Mail Chris Hannay

Vimy Pharma: Company says product won’t be available in January, still aiming for 2026

As the race among drug makers heats up to deliver a generic form of the blockbuster drug Ozempic next year, Vimy Pharmaceuticals Inc., a new entrant to the field, is aiming to produce a made-inCanada version.
The Globe and Mail (Ontario Alanna Smith

With measles elimination status in peril, country faces a wake-up call

Canadian health experts equipped with binders of information on the prolonged measles outbreak will travel in November to Mexico City, where an international committee will determine whether Canada maintains its elimination status for the disease.
WSJ: Harun Ozalp/Anadolu/Getty Images

Why Biotech’s Rally Can Last This Time

After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. The question is whether this rally marks a real recovery or just another short-lived bounce.
Photo: CBC Steven Senne/The Associated Press)

Why ‘organ chips’ could transform cancer treatment and drug testing

Lab-made technology with living tissue could guide future drug development, scientists say.
Photo: CBC News/Jacquelyn Martin/The Associated Press)

RFK Jr. cancels $500M US in funding for vaccine development, targeting mRNA

The U.S. Department of Health and Human Services, helmed by Health and Human Services Secretary Robert F. Kennedy Jr., has pulled funding and cancelled contracts for vaccine development projects involving mRNA technology.
Canada’s Life Sciences Real Estate Team - News update
Photo Illustration by Leah Abucayan/CNN

How a Trump-fueled brain drain could be the rest of the world’s brain gain

Months into President Donald Trump’s second term, as his administration wages an unprecedented war on the country’s top universities and research institutions,
Canada’s Life Sciences Real Estate Team - News update
Samyukta Lakshmi for The New York Times

World Scientists Look Elsewhere as U.S. Labs Stagger Under Trump Cuts

With the welcome mat withdrawn for promising researchers from around the world, America is at risk of losing its longstanding pre-eminence in the sciences.
Canada’s Life Sciences Real Estate Team - News update
Illustration: Ben Hickey

Trump’s attack on science is growing fiercer and more indiscriminate

It started as a crackdown on DEI. Now all types of research are being cancelled
Canada’s Life Sciences Real Estate Team - News update
Photo: Jean-Francois Monier/Agence France-Presse/Getty Images

Sanofi to Buy Vigil Neuroscience for About $470 Million

The transaction would see Sanofi purchase all of Vigil’s outstanding shares for an upfront payment of $8 a share